
Treatment options for non-small cell lung cancer (NSCLC) patients lacking actionable genetic alterations (non-AGA) remain limited, particularly after first-line (1L) therapy. This study evaluated real-world treatment patterns and outcomes among second or later-line (2L+) patients with non-AGA non-squamous...

Targeted therapies for oncogene-driven non–small cell lung cancer (NSCLC) have transformed precision oncology by enabling treatment tailored to specific molecular alterations and substantially improving outcomes in advanced disease. However, these agents are associated with distinct patterns of...

Therapeutic drug monitoring (TDM) of immune checkpoint inhibitors (ICIs) remains limited due to drug-related challenges; however, a better understanding of exposure–effect relationships may improve antitumor activity and reduce immune-related adverse events (irAEs). We conducted a prospective TDM...

Data are available upon reasonable request. Data are available upon reasonable request. Data and code are available on request from ES-Z at e.suazo.zepeda@umcg.nl. https://creativecommons.org/licenses/by-nc/4.0/...

Wedge resection by video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracoscopic surgery (RATS) are minimally invasive techniques commonly used in non-small cell lung cancer management. Although RATS has been increasingly adopted for anatomical lung resections, it is unclear whether...